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Background: In 2009, Brazil was the sole high-burden country to use three drugs [rifampin (R), isoniazid (H) and
pyrazinamide (Z)] as the standard treatment for sensitive tuberculosis, with RH in fixed-dose combination (FDC).
In December 2009, the country has adopted the FDC four-drug regimen including ethambutol (E). The rationale
was the expectation to reduce default and resistance rates, by increasing adherence to treatment and avoiding
monotherapy. However, there is no consensus on the superior effectiveness of the RHZE-FDC regimen over
RH-FDC + Z. In particular, few studies evaluated its influence on default and smear negativation rates.
Methods: We conducted a historic cohort study to assess the effectiveness of RHZE-FDC for the treatment of
tuberculosis in Brazil, measured by the rates of treatment default and smear negativation in the second month of
treatment, using secondary data from the national information system known as SINAN-TB.
Results: The RHZE-FDC had a protective effect against treatment default compared to RH-FDC + Z, reducing it
by 14%. However, it was not possible to show an effect of the RHZE-FDC on the rate of second month smear
negativation. In addition to the regimen, other well-studied individual characteristics, such as older age (over 38 years)
and higher education occupation were also protective against default. Conversely, alcoholism increased the probability
of defaulting. These programmatic findings suggests the benefits of RHZE-FDC over RH-FDC + Z.
Conclusion: Our analysis of a cohort database in a high burden country shows that compared to RH-FDC + Z,
RHZE-FDC reduces the default rates, independently of other influencing individual or health service factors.
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Tuberculosis is a public health problem in Brazil. The
country is part of the list of the 22 high-burden countries
since its first edition [1], despite the recent advances in
the control of the epidemics: incidence rates decreased
from 47 in 2001 to 36 new cases/100,000 inhabitants in
2012. Nevertheless, cure (79%) and default (12%) rates re-
main way beyond those needed to attain the millennium
development goals up to 2050 [2], to which the Brazilian
Ministry of Health (MoH) committed [3].
The advances in tuberculosis control, despite insuffi-
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unless otherwise stated.by the MoH [4]. Treatment for tuberculosis is free of
charge in the country and includes the short regimen with
rifampin since the seventies. Since the eighties, the MoH
has strengthened the primary care services, and since the
nineties, adopted the Family Health Strategy [5]. Addition-
ally, the directly observed therapy (DOT) was recommen-
ded nationally [6].
However, to face the challenge of further improvement
of operational tuberculosis indicators, new strategies were
proposed. In the end of 2009, in the hope of reducing the
rates of treatment default and halting the possible increase
in resistance rates, the Brazilian National Tuberculosis
Program (NTP) recommended the adoption of the World
Health Organization (WHO)-recommended regimen:
Rifampin (R), Isoniazid (H), Pyrazinamide (Z) and Etham-
butol (E) in fixed-combined doses (2RHZE-FDC/4RH-entral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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use at that time. This change was recommended for adults
and adolescents over 10 years [7]. It was expected that the
FDC presentation would increase treatment effectiveness
by reducing default because of the smaller number of pills
to be swallowed and because of possible better tolerance,
since standard doses of H and Z for those weighting over
50 kg were reduced from 400 to 300 mg and from 2000 to
1200 mg, respectively [8]. Additionally, the NTP expected
to halt the increase in resistance because the possibility of
monotherapy would be avoided. Moreover, the addition of
E was expected to decrease failure among patients with
suspected H-resistant TB. Despite the alarming increase
in multidrug-resistant tuberculosis in many parts of the
world, resistant rates remain low in Brazil. Finally, an
easier administration of drug supply was expected with
the “new” regimen.
However, there is no consensus in the literature on the
higher efficacy of the FDC regimen when compared to
separate drug regimens for treating tuberculosis. The
higher efficacy of the RHZE over RHZ is also poorly
studied, mainly in countries having adopted it recently.
Three systematic reviews (SR) on FDC versus separate
drug regimens for tuberculosis treatment are available
[9-11]. In the recently published (2013) SR by Albanna
et al. [9] that included 15 randomized control trials
(RCT), FDC was not associated with reduction in failure,
relapse, two-month smear/culture positivity (an early
surrogate for cure), or emergence of drug resistance as
compared to separate drug formulation. Out of five
RCTs that evaluated adherence, none favoured FDC
formulations.
Monedero & Caminero [11] also concluded that re-
garding cure and relapse rates, the FDC are not superior
to separate drugs for treating tuberculosis. Only one out
of the 15 included studies evaluated prevention of resist-
ance, and other important outcomes, such as default
rates and two-month smear negativation, were not eval-
uated in these studies. The authors concluded that the
FDC regimen should be recommended for logistic rea-
sons, costs and practicability, but not on effectiveness
grounds.
The third SR, dated 2004, is a more generic review of
FDC treatments and included two studies on tubercu-
losis [10], which did not corroborate the superiority of
this regimen.
Thus, little information is available on the effectiveness
of the RHZE-FDC in high burden countries that have
already adopted other strategies, such as DOT and
decentralization for tuberculosis control. The present
study aimed to evaluate the effectiveness of RHZE-FDC
compared to RH-FDC + Z for tuberculosis treatment in
Brazil, using a historical cohort database with secondary
data from the national surveillance information system(Sistema de Informação de Agravos de Notificação da
Tuberculose – SINAN-TB). Outcomes were treatment
default and negativation of smears at the second month
of treatment.
Methods
We conducted a non-concurrent cohort observational
study to evaluate the effects of interventions applied to
subjects diagnosed and treated in Brazilian health care
units from five cities. In Brazil, tuberculosis is a compul-
sorily notified disease and both diagnosis and treatment
are provided free of charge in the public national health
system (Sistema Único de Saúde-SUS). There are no in-
dividual selection criteria for the use of any tuberculosis
treatment regimen in new cases in Brazil. The NTP
distributes the drugs to the State and Municipal Health
Departments, which distribute to health units upon case
notification. The adoption of FDC was a programmatic
decision and its implementation was progressive, during
our study period. Once the health unit implements the
regimen, all patients will receive the same treatment.
Other regimens will only be available for intolerance or
resistance.
We selected new tuberculosis cases (untreated pre-
viously) who started treatment from October 2009 to
September 2010, residents in five eligible cities according
to the following criteria: (i) cities in the five geographical
regions of the country; (ii) with at least 120 notified
cases yearly; (iii) with different incidence rates (over and
above the national incidence rate) e (iv) with different
proportions of cases using RHZE-FDC (under 30%,
between 30 and 70% and over 70%) during the study
period.
Based on these criteria, the following cities were
selected by convenience: Goiânia (Central region, low
incidence), Manaus, Salvador and Porto Alegre (high
incidence, over 70% use of FDC-RHZE in the North,
Northeast and South regions, respectively) and Rio de
Janeiro (high incidence, under 30% of FDC-RHZE use,
Southeast region).
Since besides individual characteristics, health service-
related characteristics can influence the outcomes of this
kind of intervention, both were collected and analysed
as independent variables in a hierarchized model. Indi-
vidual variables present in SINAN and included in our
analyses were: (a) sex, (b) age group, (c) schooling, (d)
occupation, (e) living in prisons, (f ) alcoholism, (g) dia-
betes, (h) mental disease, (i) HIV infection, (j) other co-
morbidities and (k) DOT. Health care service-related
variables were: (1) facilities treating more than 125 cases
yearly, (2) DOT implemented in the unit, (3) follow-up
smears requested in the unit, (4) units having their own
laboratorial facilities, (5) complete health team, including
physician, nurse and social worker, (6) units with a social
Table 1 Distribution of pulmonary tuberculosis patients
per city according to the type of treatment from October
2009 to September 2010
City FDC-RHZE RH-FDC + Z Total
N % N % N %
Goiania 120 41.5 169 58.5 289 100.0
Manaus 1181 75.1 391 24.9 1572 100.0
Porto Alegre 859 54.3 724 45.7 1583 100.0
Rio de Janeiro 205 4.0 4942 96.0 5147 100.0
Salvador 1372 54.4 1148 45.6 2520 100.0
Total 3737 33.6 7374 66.4 11111 100.0
FDC = fixed-dose combination; R = rifampin; H = isoniazid; Z = pyrazinamide;
E = ethambutol.
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units with the Family Health Strategy, (9) units with
training activities, (10) units with primary care services
(11) units having exclusively primary care. These facility-
related data were extracted from the National Registry
of Health Care Units (Cadastro Nacional de Estab-
elecimentos de Saúde), available at cnes.datasus.gov.br,
accessed on July 12 2012, and validated with the mu-
nicipal tuberculosis program by one of the authors.
The notification system allows entry of separate drugs
used for the treatment of tuberculosis. Until the adop-
tion of the FDC-RHZE treatment, E was not used in
the country for new cases, only for retreatment cases.
Hence, we considered that reported new cases using E
after the implementation of RHZE-FDC in the city were
using the FDC formulation. Likewise, registries of new
cases using R, H and Z only were considered to be using
the previous RH-FDC + Z regimen.
The effectiveness was evaluated using two outcomes: de-
fault (according to the NTP guidelines, 30 days without
treatment or 60 days without follow up) and negativation
of smear at the second month of treatment (a hallmark for
deciding on treatment change according to the National
Guidelines) [8]. Both treatment outcomes were obtained in
the follow-up SINAN database. Details on the quality of
the SINAN database during the study period are available
elsewhere [12]. In summary, a previous quality evaluation
including completeness and consistence criteria had shown
that the database was suitable for this kind of analysis.
A hierarchized logistic regression model was used con-
sidering two levels, the individual and the collective. The
final model originated from the specific models for each
of both levels. A significance cut-off of 0.2 was consid-
ered to include variables from the specific level models.
Using the stepwise method, the final model considered a
0.05 significance cut-off.
The use of the tuberculosis surveillance database was
authorized by the Brazilian NTP under confidentiality con-
dition. The study was approved by the Institutional Review
Board of the Social Medicine Institute of Rio de Janeiro
State University and by the National Ethical Committee
(25000.219561/2011-72). Since this study was based on
secondary data, routinely collected and registered in the
national surveillance information system, informed consent
was not obtained from individual patients. The ethical
boards were aware and exempted from the consent
procedure. The intervention (treatment with RHZE-FDC)
was not the researchers decision, we just documented the
differences between patients, services and cities having
implemented the recommended regimen or not.
Results
A total of 11,111 patients were included, of whom
46% were residents in Rio de Janeiro, situated in theSoutheast region, which concentrates more than half
the Brazilian population; 23% in Salvador, 14% in Manaus
and Porto Alegre each and 3% in Goiânia. Table 1 shows
the distribution of patients in the cities according to the
type of treatment.
Patients who received the RHZE-FDC regimen were
more likely to be older, illiterate, alcoholics, have other co-
morbidities considering a 0.05 significance level; while
those under RH-FDC + Z were more likely to be in prisons
(Table 2). These differences indicated that patients’ hetero-
geneity should be taken into account in the evaluation of
the effect of the intervention on the outcomes. They could
be also due to differences overtime, since RHZE-FDC
patients corresponded to more recent notifications in
the same city.
Regarding health service characteristics, patients re-
ceiving RHZE-FDC were more likely to be treated in
units treating less than 125 cases per year, with DOT
implemented, performing follow-up smears and having
exclusively primary care services. Conversely, those re-
ceiving RH-FDC + Z were more likely to have complete
health teams, a social service, community health agents,
the Family Health Strategy, teaching activities and pri-
mary care (Table 3).
The effect of FDC-RHZE on treatment default
In the present study period, in the five cities, default was
the treatment outcome in 14% of new cases. This rate
varied from 7.5% in Salvador to 20.3% in Porto Alegre.
The FDC-RHZE regimen appears to have a protective
effect against default compared to the RH-FDC + Z regi-
men but this lost significance when adjusted for individ-
ual characteristics. Older age and higher education
occupation had a protective effect while alcoholism and
HIV co-infection were directly associated to defaulting
(Additional file 1: Table S1).
When health clinic characteristics are considered, the
FDC-RHZE regimen has a protective effect, even when
adjusted for the characteristics that influence default.
Table 2 Characteristics of pulmonary tuberculosis
patients according to the type of treatment from October
2009 to September 2010
Characteristics FDC-RHZE RH-FDC + Z Total p-value
N % N % N %
Age
<38 years 1952 52.2 4100 55.6 6052 54.5 0.001
≥38 years 1785 47.8 3.274 44.4 5059 45.5
Total 3737 7374 11111
Sex
Feminine 1301 34.8 2539 34.4 384 34.6 0.689
Masculine 2436 65.2 4835 65.6 7271 65.4
Total 3737 7374 11111
Illiteracy
No 3487 96.4 7035 97.4 10522 97.0 0.003
Yes 132 3.7 189 2.6 321 3.0
Total 3619 7224 10843
Higher education
occupation
No 2773 97.0 5488 96.6 8261 96.7 0.384
Yes 87 3.0 193 3.4 280 3.3
Total 286 5681 8541
Living in prisons
No 3362 91.8 6320 87.9 9682 89.2 0.000
Yes 302 8.2 869 12.1 1171 10.8
Total 3664 7189 10853
Alcohol use
No 2835 81.8 5256 85.8 8091 84.3 0.000
Yes 632 18.2 870 14.2 1502 15.7
Total 3467 6126 9593
Diabetes
No 3174 92.4 5505 91.6 8679 91.9 0.174
Yes 262 7.6 505 8.4 767 8.1
Total 3436 6010 9446
Mental disorder
No 3363 97.8 5896 97.4 9259 97.5 0.194
Yes 76 2.2 160 2.6 236 2.5
Total 3439 6056 9495
Other co-morbidities
No 2640 81.3 4687 84.0 7327 83.0 0.001
Yes 608 18.7 896 16.1 1504 17.0
Total 3248 5583 8831
DOT
No 2746 75.9 5390 76.0 8136 75.9 0.954
Yes 872 24.1 1706 24.0 2578 24.1
Total 3618 7096 10714
Table 2 Characteristics of pulmonary tuberculosis
patients according to the type of treatment from October
2009 to September 2010 (Continued)
HIV status
Negative 1267 74.7 2011 76.7 3278 75.9 0.135
Positive 430 25.3 614 23.4 1044 24.1
Total 1697 2625 4322
FDC = fixed-dose combination; R = rifampin; H = isoniazid; Z = pyrazinamide;
E = ethambutol, DOT = directly observed treatment.
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was the most important characteristic protecting against
default. Other protective characteristics were DOT adop-
tion and follow-up smears (Additional file 1: Table S2).
The final hierarchized model including both individual
and health facility characteristics showed that the FDC-
RHZE has a 14% protective effect against default, detect-
able when excluded the influence of the other aspects
that are also associated with default (Table 4).
The effect of FDC-RHZE on negativation of second month
follow-up smears
The information on follow up smear at the second
month was available for 2,792 (25.1%) patients. Negati-
vation of second month smear occurred in 68% of them.
The highest rate of negativation was observed in Manaus
(74%) and the lowest in Rio de Janeiro (56%).
Compared to those using RH-FDC + Z, patients re-
ceiving FDC-RHZE had a higher probability of having a
negative smear on the second month of treatment. The
individual characteristics influence little this outcome, a
part from a using DOT (Additional file 1: Table S3).
However, when simultaneously considering the health
facility-related characteristics, the protection by FDC-
RHZE is not sustained. Patients treated in units with
more than 125 cases yearly are less likely to have a nega-
tive smear on the second month, while the inverse is ob-
served among those treated in units that adopted DOT
or have exclusively primary care services (Additional
file 1: Table S4).
The final, hierarchized model shows that FDC-RHZE
has no influence on the second month-smear nega-
tivation. The other variables with an influence in the
specific model sustained significance in the final model
(Table 5).
Discussion
In the present study, default rate was high (14%), signifi-
cantly higher than the rate tolerated by WHO (5%) [13].
This is not a surprise, given the default rates reported in
the country as a whole [3]. Our analysis showed that as
compared to RH-FDC + Z, RHZE-FDC had a protective
effect of 14% against defaulting from tuberculosis
Table 3 Characteristics of health care units where
pulmonary tuberculosis patients were treated according
to the type of treatment from October 2009 to
September 2010
Characteristics FDC-RHZE RH-FDC + Z Total p-value
N % N % N %
The unit assists over 125 cases yearly
No 1989 53.2 3574 48.5 5563 50.1 0.000
Yes 1748 46.8 3800 51.5 5548 49.9
Total 3737 7374 11111
The unit offers DOT
No 440 11.8 1621 22.0 2061 18.6 0.000
Yes 3297 88.2 5753 78.0 905 81.5
Total 3737 7374 11111
The unit requests follow up smears
No 283 7.6 2135 29.0 2418 21.8 0.000
Yes 3454 92.4 5239 71.1 8693 78.2
Total 3737 7374 11111
The unit has a laboratory facility
No 2477 66.3 4763 64.6 7240 65.2 0.070
Yes 1260 33.7 2611 35.4 3871 34.8
Total 3737 7374 11111
The unit has a complete team with physician, nurse and social worker
No 2153 57.6 1872 25.4 4025 36.2 0.000
Yes 1584 42.4 5502 74.6 7086 63.8
Total 3737 7374 11111
The unit has a Social Service
No 2153 57.6 1872 25.4 4025 36.2 0.000
Yes 1584 42.4 5502 74.6 7086 63.8
Total 3737 7374 11111
The unit has community health agents
No 2626 70.3 2980 40.4 5606 50.5 0.000
Yes 1111 29.7 4394 59.6 5505 49.6
Total 3737 7374 11111
The unit has the Family Health Program
No 2664 71.3 3573 48.5 6237 56.1 0.000
Yes 1073 28.7 3801 51.6 4874 43.9
Total 3737 7374 11111
The unit has training activities
No 3534 94.6 6249 84.7 9783 88.1 0.000
Yes 203 5.4 1125 15.3 1328 12.0
Total 3737 7374 11111
The unit has primary care
No 2692 72.0 2205 29.9 4897 44.1 0.000
Yes 1045 28.0 5169 70.1 6214 55.9
Total 3737 7374 11111
Table 3 Characteristics of health care units where
pulmonary tuberculosis patients were treated according
to the type of treatment from October 2009 to
September 2010 (Continued)
The unit has exclusively primary care
No 2832 75.8 6543 88.7 9375 84.4 0.000
Yes 905 24.2 831 11.3 1736 15.6
Total 3737 7374 11111
FDC = fixed-dose combination; R = rifampin; H = isoniazid; Z = pyrazinamide;
E = ethambutol, DOT = directly observed treatment.
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for second month-smear negativation.
Studies comparing FDC and separated drug outcomes
using secondary notification data were not found in the
literature. However, the set of controlled trials in the last
two decades that analysed FDC versus single drugs for
tuberculosis treatment found no protective effects on
cure, relapse or smear negativation rates [11]. However,
programmatic, operational studies can have different
outcomes when compared with the controlled conditionsTable 4 Risk factors for TREATMENT DEFAULT among
pulmonary tuberculosis patients from October 2009 to
September 2010 (hierarchized model)
Characteristics % OR 95% CI adjOR 95% CI
FDC-RHZE
No 66.4 1 1
Yes 33.6 0.811 0.723 - 0.910 0.862 0.523 - 0.998
Age
<38 years 54.4 1 1
≥38 years 45.5 0.620 0.555 - 0.692 0.599 0.484 - 0.742
Higher education
occupation
No 97.0 1 1
Yes 3.0 0.355 0.217 - 0.582 0.223 0.081 - 0.610
Alcohol use
No 81.8 1 1
Yes 18.2 1.555 1.349 - 1.793 1.767 1.377 - 2.268
The unit offers DOT
No 18.5 1 1
Yes 81.5 0.946 0.826 - 1.082 0.979 0.850 - 1.128
The unit requests follow up smears
No 21.7 1 1
Yes 78.3 0.914 0.805 - 1.037 0.947 0.826 - 1.087
The unit has a laboratory facility
No 65.2 1 1
Yes 34.8 0.904 0.808 - 1.012 0.892 0.796 - 1.001
Bold numbers are statistically significant findings. FDC = fixed-dose
combination; R = rifampin; H = isoniazid; Z = pyrazinamide; E = ethambutol,
DOT = directly observed treatment; OR = odds ratio; adjOR = adjusted odds
ration; CI = confidence interval.
Table 5 Risk factors for SECOND MONTH SMEAR
NEGATIVATION among pulmonary tuberculosis patients
from October 2009 to September 2010 (hierarchized model)
Characteristics % OR 95% CI adjOR 95% CI
FDC-RHZE
No 66.4 1 1
Yes 33.6 1.104 0.932 - 1.307 1.164 0.999 - 1.372
DOT
No 75.9 1 1
Yes 24.1 1.450 1.208 - 1.739 1.373 1.137 - 1.658
The unit assists over 125 cases yearly
No 50.1 1 1
Yes 49.9 0.782 0.663 - 0.922 0.817 0.686 - 0.974
The unit has exclusively primary care
No 84.4 1 1
Yes 15.6 1.289 1.065 - 1.559 1.336 1.099 - 2.126
Bold numbers are statistically significant findings. FDC = fixed-dose combination;
R = rifampin; H = isoniazid; Z = pyrazinamide; E = ethambutol, DOT = directly
observed treatment; OR = odds ratio; adjOR = adjusted odds ration;
CI = confidence interval.
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the MoH database, previously shown to be suitable for
this type of analyses, we did not find such protection ei-
ther, at least when compared to RH-FDC + Z. The out-
come default using FDCs has been less explored in the
literature. Both older (1987) [14] and more recent (2002)
[15] studies did not detect any difference in default rates,
although smear negativation rates increased with FDC in
the former, as well as in more recent studies [16].
The most important experimental study on this matter
was recently published by Lienhardt et al. [17]. This ran-
domized controlled trial known as The Study C was con-
ducted in 11 sites in Africa, Asia and Latin America
between 2003 and 2008. Unlike ours, this study aimed to
evaluate safety and effectiveness of FDC-RHZE com-
pared to RHZE in separate formulation, and the main
outcome was a negative culture at 18 months after
treatment onset. The study concluded that the non-
inferiority condition was attained and that FDCs are
better accepted because of the potential advantages
associated with their administration as compared to
the separate drugs. Unlike the previously reported studies,
ours uses an observational methodology, and two different
regimens (not only the formulation) are compared. Thus,
we cannot conclude that the benefits of the RHZE-FDC
regimen are due exclusively to its fixed-dose presentation,
since doses were different and an additional drug (E) was
included.
Because randomization is not possible in the used
study design, we adjusted for potential confounding
variables, both at the individual and at the health servicelevel. Our results indicate that at the individual level, be-
sides the regimen, patients with older age and higher
education occupation, a proxy for socioeconomic status,
were less likely to default, while alcoholism increased
the risk for default. These individual variables were
largely explored in the literature and there is solid evi-
dence to support their role in defaulting, as summarized
in a meta-analysis [18,19]. Other characteristics not
present in SINAN database, such as adverse events and
unemployment, and other not amenable in this king of
study, such as knowledge and believes, have also been
shown to influence default rates [18,19] It is beyond of
the scope of the present study to discuss each of these
factors. They were only analysed to verify if the effect of
the RHZE-FDC regimen was spurious or independent of
these variables, since there was no randomization. Like-
wise, although drug bioavailability is another important
factor explored in FDC studies, this discussion is out of
the scope of the present analysis [20,21]. Finally, regarding
the laboratory outcome, negative culture at 18 months,
recommended as an endpoint by international bodies to
evaluate failure and relapse, was not available in the Bra-
zilian surveillance database. Second-month negativation is
indeed, not a sensitive surrogate for these outcomes. Our
choice of the second-month negativation as an outcome
was however justified because [1] it was the best available
information, since it is a national recommendation to
request culture if the mandatory sputum smear at the
second month is positive and [2] the rationale for the
regimen replacement was high rates of default and of
resistance, and the second-month negativation is a good
predictor of resistance.
Adherence is probably the factor that most influence
the effectiveness of any treatment [22]. This is the rea-
son why we chose default as one of the outcomes in the
present analysis. Besides influencing effectiveness, irregular
and incomplete tuberculosis treatments are also respon-
sible for emergence of multidrug resistant-tuberculosis
(which we could not evaluate).
Interestingly, while only individual characteristics and
the FDC regimen had an effect on default, only health
care characteristics, such as DOT, service organization
and workload influenced the smear negativation rate.
The Family Health Strategy increases the bonding be-
tween the community and the health services [5]. This
attachment, mostly developed through the community
health agent, may be at the origin of better tuberculosis
treatment outcomes in Brazil [19,23]. Likewise, despite
the controversy [24,25], DOT has been recognized as an
excellent strategy that has prevented 4.6–6.3 million
deaths between 1995 and 2009 in the world since its
implementation [26]. Finally, the importance of a multi-
disciplinary team to deal with this socially determined
disease could not be overemphasized.
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our sample might have been a result of selection bias.
However, they had the same profile as those not in-
cluded in the analyses (data not shown) thus we do not
believe our results are a consequence of bias. Another
possible limitation would be the quality of data itself,
since the source of the database was the routine sur-
veillance information system. Nevertheless, a previous
quality control [12] showed that the data gathered
was adequate for analysis. The sputum negativation
outcome was available only for one quarter of pa-
tients, reducing the statistical power for this outcome.
However, it is unlikely that it jeopardizes the validity
of the results. In addition, despite selecting new cases,
multiresistant cases could have been included, but
again, it is unlikely that those patients could have se-
lectively received one of the treatment regimens. Finally,
a classification bias might have occurred because we
considered any RHZE as using FDC formulation in the
period of the intervention. Although this can have over-
estimated the number of patients under FDC, it is
unlikely that it had any effect on the analysis of individ-
ual and collective factors associated with the selected
outcomes.
On the other hand, the inclusion of several cities with
heterogeneous health unit performance and different
probabilities of use of the treatment regimens allowed a
wide spectrum of individual and health system character-
istics, necessary for adjustments of the effect measures.
For example, most patients in Rio received the RH-FDC +
Z regimen in heterogeneous health units. This is the rea-
son why we adjusted for health unit characteristics and
not for cities. In addition, the option of conducting a study
with an internal comparison group instead of a “before
and after” design reduces the chances of observing effects
(such as default rates) that could be attributed to other
non-controlled interventions concurrent to the implemen-
tation of the new regimen.
Although observational studies are not ideal for eva-
luating programmatic interventions, this was the only
possible method because the intervention was already
launched when we planned the study. On the other
hand, it had the advantage of showing the pragmatic effect
of the “new” treatment on notified cases. Retrospectively,
it strengthens the Brazilian NTP decision to change the
treatment in the country. As new, shorter regimens are
under investigation and expected for a near future (as
pointed at http://www.tballiance.org/downloads/Pipeline/
TBA%20Pipeline%20Q1%202015%282%29.pdf), it is im-
portant to plan cluster randomized studies to evaluate the
effectiveness of the intervention at the health service level.
However, secondary data from the national surveillance
system is also a source of reliable and useful information
in early adopter countries.Conclusions
In summary, our analysis of a cohort database in a high
burden country shows that compared to RH-FDC + Z,
RHZE-FDC reduces the default rates by 14%, independ-
ently of other influencing individual or health service
factors, which eventually have a stronger effect.
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